
Tanya du Plessis, Brand Insights Contributor, VP, Data Strategies & Solutions, Bioforum the Data Masters
Articles by Tanya du Plessis, Brand Insights Contributor, VP, Data Strategies & Solutions, Bioforum the Data Masters


Welcome back to the Forum for EmergingBio's Outsourcing Decisions!

Welcome back to the Forum for EmergingBio's Outsourcing Decisions! There is nothing quite like protocol amendments to put the brakes on a clinical trial’s momentum, which is why, in this blog, we are turning our attention to how to face this challenge head on.

As the biopharma industry traverses unchartered waters amid the COVID-19 crisis and doubles down on its efforts to bring new therapies to market faster, cheaper and without affecting quality, the success of strategic partnerships and functional service provider models will become more critical than ever before.
Latest Updated Articles
- Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials
Published: February 13th 2025 | Updated: March 4th 2025
- Accelerate Inclusive Enrollment and Delivery with Lightship
Published: February 19th 2025 | Updated: February 26th 2025
- Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
- Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent Adoption
Published: April 28th 2021 | Updated:
- Sticking to the Plan: Undue Burden Created by Protocol Deviations
Published: July 26th 2024 | Updated:
- Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple Myeloma
Published: January 31st 2024 | Updated: